Ardelyx Reports Third Quarter 2015 Financial Results

Go back to Ardelyx Reports Third Quarter 2015 Financial Results

Ardelyx (ARDX) Misses Q3 EPS by 22c

November 12, 2015 9:27 AM EST

Ardelyx (NASDAQ: ARDX) reported Q3 EPS of ($0.70), $0.22 worse than the analyst estimate of ($0.48).

Two key clinical development programs accelerated, tenapanor in IBS-C and RDX022 in hyperkalemia Initiation of a second Phase 3 clinical trial for tenapanor in IBS-C expected December 2015 Results of a... More